FILOWM4-WaZaBi: Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients previously treated for Waldenström macroglobulinemia
Phase 1
Active, not recruiting
- Conditions
- Patients with Waldenstrom macroglobulinemia and have received at least one prior line of treatmentMedDRA version: 25.1Level: LLTClassification code: 10054695Term: Waldenstrom´s macroglobulinemia Class: 10029104MedDRA version: 20.1Level: HLTClassification code: 10047802Term: Waldenstrom's macroglobulinaemias Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10047801Term: Waldenstrom's macroglobulinaemia Class: 100000004864Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2023-505781-28-00
- Lead Sponsor
- French Innovative Leukemia Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 102
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method